← Back to Search

Direct Lytic Agent

Exebacase for Staphylococcus Aureus Endocarditis (DISRUPT Trial)

Phase 3
Waitlist Available
Research Sponsored by ContraFect
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 60
Awards & highlights

DISRUPT Trial Summary

This trial will study whether exebacase is effective and safe in addition to standard of care antibiotics for treating patients with Staphylococcus aureus bloodstream infections.

Eligible Conditions
  • Staph Bacteremia
  • Staphylococcus Aureus Endocarditis

DISRUPT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 60 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical Responder Rate at Day 14 in the MRSA Population in the Microbiological Intent-to-treat (mITT) Analysis Set
Treatment-emergent Adverse Events (TEAEs) Through Day 60
Secondary outcome measures
30-day survival in the MRSA population
Clinical responder rate at Day 14 in all S. aureus patients
Clinical responder rate at Day 60 in all S. aureus patients
+2 more

DISRUPT Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExebacaseExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

ContraFectLead Sponsor
3 Previous Clinical Trials
141 Total Patients Enrolled
1 Trials studying Staphylococcus Aureus Endocarditis
121 Patients Enrolled for Staphylococcus Aureus Endocarditis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
2019. "Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04160468.
~49 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top